Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TET2 | Q6N021 | 5/20 | 0.39 |
| ▸ | TET3 | O43151 | 1/20 | 0.37 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19543222 | 0.78 | TSHR (0.32) | — | |
| SCHEMBL31435 | 0.78 | TET2 (0.37) | TET2TET3TET1GRIK1GRIK2 | |
| SCHEMBL6030920 | 0.77 | TET2 (0.35) | TET2TET3TET1GRIK1GRIK2 | |
| SCHEMBL25832433 | 0.77 | — | — | |
| SCHEMBL2331153 | 0.76 | TDP1 (0.41) | — | |
| Itaconate SCHEMBL28431007 | 0.74 | ALOX15 (0.60) | TET2TET3TET1GRIK1GRIK2 | |
| SCHEMBL28251693 | 0.74 | ALOX15 (0.38) | TET2TET3TET1GRIK1GRIK2 | |
| SCHEMBL19543217 | 0.74 | TDP1 (0.30) | — | |
| SCHEMBL21986236 | 0.74 | TBXAS1 (0.38) | TET2TET3TET1GRIK1GRIK2 | |
| SCHEMBL190142 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116332900-A | Olefin compound and synthesis method thereof | 华中科技大学 | 2023-06-27 | — | — | CN | claimed |
| EP-0831756-A1 | BISPHOSPHONATE CEMENT COMPOSITION TO PREVENT ASEPTIC LOOSENING OF ORTHOPEDIC IMPLANT DEVICES | Merck & Co., Inc. (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1996039107-A1 | BISPHOSPHONATE CEMENT COMPOSITION TO PREVENT ASEPTIC LOOSENING OF ORTHOPEDIC IMPLANT DEVICES | MERCK & CO., INC. (US) | 1996-12-12 | — | — | WO | claimed |
| WO-2024249950-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | BIOMEA FUSION, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| CN-116332900-A | Olefin compound and synthesis method thereof | 华中科技大学 | 2023-06-27 | — | — | CN | disclosed |
| EP-3007858-A1 | LOW SURFACE ROUGHNESS POLISHING PAD | Cabot Microelectronics Corporation (US) | 2016-04-20 | — | — | EP | disclosed |
| EP-2953648-A1 | NANOPARTICLES CONTAINING A TAXANE AND THEIR USE | ANP Technologies, Inc. (US) | 2015-12-16 | — | — | EP | disclosed |
| WO-2014200726-A1 | LOW SURFACE ROUGHNESS POLISHING PAD | CABOT MICROELECTRONICS CORPORATION (US) | 2014-12-18 | — | — | WO | disclosed |
| EP-2648760-A2 | SMART POLYMERIC NANOPARTICLES WHICH OVERCOME MULTIDRUG RESISTANCE TO CANCER CHEMOTHERAPEUTICS AND TREATMENT-RELATED SYSTEMIC TOXICITY | The Johns Hopkins University (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012078831-A2 | SMART POLYMERIC NANOPARTICLES WHICH OVERCOME MULTIDRUG RESISTANCE TO CANCER CHEMOTHERAPEUTICS AND TREATMENT-RELATED SYSTEMIC TOXICITY | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-06-14 | — | — | WO | disclosed |
| US-20080103311-A1 | Retroviral protease inhibitors | PHARMACIA CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| EP-0558603-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0558630-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0558657-A1 | RETROVIRAL PROTEASE INHIBITORS. | MONSANTO CO (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0554400-A1 | RETROVIRAL PROTEASE INHIBITORS. | MONSANTO CO (US) | 1993-08-11 | — | — | EP | disclosed |
| WO-1992008700-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008701-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008688-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008699-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008698-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103311-A1 | Retroviral protease inhibitors | PREP, DNPEP, SERPINB1 | TET2 3289/4885TET3 2733/4885TET1 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.